Navigation Links
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Date:6/12/2008

- APD125 Significantly Improved Key PSG Parameters of Sleep Maintenance -

- Phase 2b Subjective Study Ongoing -

SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment of insomnia in an oral presentation at the SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies in Baltimore, Maryland.

APD125 is an oral drug candidate discovered by Arena that is being evaluated for the treatment of insomnia in patients who have difficulty maintaining sleep after initial sleep onset. When compared to placebo in the Phase 2a clinical trial, patients treated with APD125 experienced statistically significant improvements in polysomnographic (PSG) measurements of sleep maintenance, or the ability to maintain sleep during the night after falling asleep. These improvements were achieved without any next day impairment of cognition or coordination.

"APD125 is a potential next generation treatment for improving sleep maintenance that could meet the needs of many patients looking to achieve better 'quality sleep'," stated Dr. Thomas Roth of Henry Ford Hospital, who interpreted the PSG data for the Phase 2a trial. "In the trial, APD125 clearly demonstrated robust sleep maintenance properties without any apparent pattern of side effects associated with the drug."

Arena is currently evaluating the effects of APD125 on patients' subjective assessment of sleep in a Phase 2b study.

APD125 Phase 2a Study Results

In a Phase 2a clinical trial, APD125 significantly improved several PSG endpoints measuring improve
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
4. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
5. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
7. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Across the global healthcare landscape, ... in clinical development, market education, and regulatory compliance. As ... Affairs function is expected to increase in prominence and ... According to research by benchmarking firm, Best Practices, ... dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... March 27, 2015 Object recognition technology has ... impaired and elderly. The VelaSense ® ... lead more independent, productive and fulfilling lives. VelaSense ® ... allow users to identify objects from a one million ... create customized object databases for personal use. ...
(Date:3/27/2015)... Ga. , March 27, 2015  Holographic Optical ... in the field of holographic medical imaging, is entering ... its Kickstarter campaign. Launching on April 20 th , ... and Voxbox Pro. The 8-inch and 22-inch displays will ... home for the first time. In addition to the ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg, 10 mg, 15 mg, and 20 mg. This product ... ® , which is indicated for the treatment of schizophrenia ...
... Young Innovations, Inc. (NASDAQ: YDNT ) today announced sales ... Sales for the first quarter of 2012 were ... the first quarter of 2011. Income from operations increased 5.3% to ... in the first quarter of 2011. Net income increased 5.6% to ...
Cached Medicine Technology:Mylan Launches Generic Version of Zyprexa® Tablets 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 An ... a problem which could prove critical to organizations that ... testing, a critical aspect of data security, is worsening ... industry data security report, every major category out of ... and penetration testing. “With all the craziness that has ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:3/28/2015)... Purity Products®, a leading direct to ... of their revolutionary new weight loss product, MuffinStop™. ... placebo-controlled clinical studies to be effective in reducing ... is a combination of two traditionally used botanical ... to create one of the most innovative weight ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
... Researchers from the University of Pennsylvania School of Medicine ... determines the development of many cell types, and is ... for the maintenance of stem cells. The findings appear ... inhibitors of Notch may not affect bone marrow stem ...
... 1995, Tapped to Steer the World,s Largest Organization ... WHITE PLAINS, N.Y., April 10 The Leukemia & ... chief executive,officer, with the task of leading the world,s ... strives to find cures and,prolong and enhance the lives ...
... survived exposure, study reports, , , THURSDAY, April 10 (HealthDay ... anthrax vaccine that provides protection against the potentially deadly ... and combining two of anthrax,s lethal toxins, the researchers ... be more effective than vaccines that contain just one ...
... - 7,000 deaths ... significantly reduces pharmacy error risk, - Half of consumers choose their ... ... April 10 One-third of America,s 225,million prescription-takers now report experiencing ...
... N.J., April 10 Hooper Holmes,(Amex: HH ) today ... Executive Officer and that Benjamin A. Currier will continue as,Chairman ... a member of the,Board since May 30, 2007, had been ... basis on February 6, 2008., John W. Remshard, who ...
... state,s elderly, disabled, and ... ... cut hundreds of millions of dollars from Medicaid,programs for the elderly, disabled ... the leaders of Florida,s safety net,hospitals warned today., Besides jeopardizing the ...
Cached Medicine News:Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:The Leukemia & Lymphoma Society Announces Appointment of New President and CEO 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 3Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 3Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 2Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 3Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 2Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 3
RIA kit for the quantitative determination of autoantibodies to IA-2 in serum...
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum...
Inquire...
Inquire...
Medicine Products: